TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Von Hippel-Lindau Disease Genetic Epidemiology Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Eligible patient volunteers are those who:~1. have been enrolled in protocol 89-C-0086;~2. are a member of a family in which at least one person has been diagnosed with VHL at NIH; and~3. are at least 13 years of age.~Patient volunteers seen under protocol 89-C-0086 who have been diagnosed with VHL, are at risk of VHL, or are unaffected are all eligible for study.~Additional families screened throughout the field period and meeting all eligibility criteria will also be able to participate.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Non-operative Management of Pediatric Appendicitis With an Appendicoltih

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : 7-17 years~* Abdominal pain \</= 48hours prior to receiving antibiotics~* White Blood Cell Count \>5 but \< 18~* US or CT confirmed early appendicitis plus:~  * US: \</=1.1 cm in diameter, presence of appendicolith~ * CT: \</= 1.1cm in diameter, presence of appendicolith~Exclusion Criteria:~* Positive urine pregnancy test~* Pain \> 48 hours prior to first antibiotic dose~* Diffuse peritonitis~* History of chronic intermittent abdominal pain~* White Blood Cell count ≤ 5 or ≥ 18~* Absence of appendicolith or any evidence on imaging studies concerning for evolving perforated appendicitis including abscess or phlegmon

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Non-operative Management (Type: EXPERIMENTAL): Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
- Surgery (Type: NO_INTERVENTION): Usual care with urgent appendectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically/cytologically proven, non-metastatic (M0) adenocarcinoma of the prostate.~* Life expectancy of \> 12 months.~* Initiation of treatment with the luteinizing hormone-releasing hormone agonist (LHRH-a) Lupron no more than 15 days prior or 30 days following, baseline visit.~* Requiring treatment with LHRH agonists for prostate cancer, for a duration of at least 12 months from baseline.~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2~* Prior to any study-specific procedures, subject (and/or their legally authorized representative) has voluntarily signed and dated an informed consent form.~Exclusion Criteria:~Bone Metastases Current or previous use with in past 12 months of bisphosphonate. Known hypersensitivity to LHRH. Hypocalcaemia. Severe renal impairment, Abnormal liver function, Hypothyroidism, Hyperthyroidism, Bilateral hip replacement.~Use of LHRH or anti-androgen medication within last 12 months. Abnormalities of esophagus which delay esophageal emptying. Inability to stand or sit upright for at least 30 minutes.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients (age 6-21) who will receive cranial radiotherapy for brian tumors. This could include but is not limited to: low grade glioma, high grade glioma (to include grade III but not grade IV glioma), germ cell tumors, primitive neuroectodermal tumors, craniopharyngioma, or medulloblastoma.~* Patients should, in the estimate of the treating physician, be anticipated to have a median survival of greater than 1 year.~Exclusion Criteria:~* Patients with previous Central Nervous System (CNS) radiation or or CNS tumors that, in the judgement of the investigators, are likely to undergo progression during or shortly after radiotherapy are excluded.~* Patients with glioblastoma, multiforme, gliosarcoma, diffuse pontine glioma, or other tumors presumed to have expected median survival per the investigators of less than 1 year.~* Patients who require sedation for Magnetic Resonance Imagining (MRI)are excluded.~* Patients at risk for nephrogenic systemic sclerosis will be excluded as a safety precaution due to the contrast used in the scans.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Primary Brain Tumor (Type: OTHER): Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Positive Airway Pressure (CPAP) Ventilation Using a Novel Full-Face Mask Versus Conventional Helmet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ongoing or recent history of respiratory failure (either primary or secondary)~* PaO2 \<60 mmHg if breathing room air or PaO2/FiO2 \<300 mmHg if receiving supplemental oxygen~* Acute dyspnea with respiratory rate \>25 bpm and accessory muscle recruitment and/or paradoxical abdominal breathing~Exclusion Criteria:~* Refusing noninvasive ventilation~* Comatose (Glasgow Coma Scale \<8) or unable to maintain a patent airway~* Hemodynamically unstable (systolic blood pressure \<80 mmHg on recruitment, or receiving vasopressors/inotropes; ongoing angina/myocardial infarction; newly-developed arrhythmia with hemodynamic impact)~* Having recently (≤2 weeks) undergone oesophageal or upper respiratory tract surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Helmet (Type: ACTIVE_COMPARATOR): Patients in this group will receive continuous positive airway pressure delivered through a helmet connected to a high-flow reservoir system.
- Mask (Type: EXPERIMENTAL): Patients in this group will receive continuous positive-airway pressure delivered through a novel full-face mask connected to a high-flow system. Expiratory pressure will be maintained using an expiratory valve connected to a T-tube.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Require primary or secondary nerve injury repair with Hollow Nerve Conduit or AVANCE™ in at least 1 digital nerve;~* Undergo End to End nerve to nerve graft coaptation on both the proximal and distal portion of the nerve gap in the AVANCE™ group or nerve entubulation in the Hollow Nerve Conduit group;~* Be willing to comply with all aspects of the treatment and evaluation schedule over a 12 Month duration; and~* Sign and date an IRB-approved written informed consent prior to initiation of any study procedures, including screening procedures.~Exclusion Criteria:~* Nerve gaps of \< 5 mm or \> 20 mm;~* Estimated distance of regeneration of \>125 mm (distance from injury site to sensory target)~* Nerve crush or avulsion injuries;~* Incomplete nerve transections;~* Injury requiring replantation of target digit;~* Contralateral digital injuries corresponding to the target digit;~* Nerve injuries in the affected limb proximal to the crease of the wrist;~* End to side nerve repair;~* Injuries with significant vascular damage which may impair adequate perfusion of the target limb;~* Subjects who are undergoing treatment with chemotherapy, radiation therapy, or other know treatment which affects the growth of neural and/or vascular system;~* Use of bovine collagen based hollow nerve conduit in a subject with known or suspected bovine sensitivity;~* Subjects age ≤18 years or ≥70 years;~* History neuropathy, diabetic or any other known neuropathy;~* Secondary nerve repair \>12 weeks post initial injury;~* Currently enrolled in another investigational study;~* Expected use of medications during the study that are known to cause peripheral neuropathy;~* History or Reynaud's or other disorder known to compromise circulation or sensation in the upper extremity; and~* Any subject who at the discretion of the Investigator is not suitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Avance Nerve Graft (Type: ACTIVE_COMPARATOR): Commercially available Avance Nerve Graft for repair of nerve gap
- Hollow Tube Conduit (Type: ACTIVE_COMPARATOR): Commercially available hollow tube conduit for repair of nerve gap.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve American Joint Committee on Cancer (AJCC) stage I-IVa squamous cell carcinoma of the head and neck with no definitive evidence of metastatic disease~* Sufficient vision, writing, and communication ability to complete the interviews and assessment tool~* Signed informed consent~Exclusion Criteria:~* Patients who are enrolled in other head and neck cancer treatment protocols are permitted to participate in this study if a) the other protocol permits this and b) the other protocol does not utilize the HNPS~* Patients who have previously undergone cancer treatment or are presently undergoing additional cancer treatments~* Patients who have already undergone unsuccessful curative-intent surgery on their head and neck cancer~* Patients, who have had a major surgery (defined as requiring general anesthesia but not including tonsillectomy, neck dissection, or panendoscopy \[triple endoscopy or examination under general anesthesia\]), or significant traumatic injury within 4 weeks of the study; patients who have not recovered from the side effects of any of the above surgeries~* Patients unwilling to or unable to comply with the protocol~* Patients unable to communicate with the interviewer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational (patient preferences) (Type: None): Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Ischemic Preconditioning to Prevent Contrast Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing coronary angiography for stable or unstable coronary artery disease~* eGFR less than or equal to 60 mL/min/1.73 m2~Exclusion Criteria:~* Subjects with known upper extremity vascular disease~* Subjects with systolic blood pressure differential of 10 mmHg or higher in the upper extremities~* End stage renal disease on peritoneal or hemodialysis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RIPC (Type: ACTIVE_COMPARATOR): Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
- Controls (Type: SHAM_COMPARATOR): Participants will have routine blood pressure measurements will be obtained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female (post menopausal and/or surgically sterile)~* Aged 18 to 70 years~* Treatment naïve subjects with fasting blood glucose levels of 150-220 mg/dL, hematocrit of \>/= 35% and HbA1c levels of \>/= 7% and \</= 10.0%~* Subjects on antidiabetic therapy with fasting blood glucose levels of 100-200 mg/dL, hematocrit of \>/= 35%, and HbA1c levels of \>/= 6.5% and \</= 9.0%~Exclusion Criteria:~* Greater than 3 severe hypoglycemic episodes within six months of screen~* Pregnant, breastfeeding, or intends to become pregnant~* Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT greater than 1.5 times the upper limit of normal~* History of hepatitis B surface antigen, hepatitis C antibody, or HIV~* Complications of diabetes (e.g., neuropathy, nephropathy, and retinopathy)~* Clinically significant and currently active diseases~* Clinically significant abnormalities in medical history, physical examination, or laboratory examination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of PTSD, as derived from the Clinician-Administered PTSD Scale (CAPS)~* Stabilized on any necessary medications for at least 4 weeks prior to study entry~* Score of greater than 4 on the CAPS Recurrent Distressing Dreams item (maximum score of 8)~* Score of greater than 4 on the CAPS Difficulty Falling or Staying Asleep item (maximum score of 8)~* Agrees to use an effective form of contraception throughout the study~Exclusion Criteria:~* Any acute or significant chronic medical illness~* Any unstable medical condition~* Unstable angina, recent heart attack, history of congestive heart failure, pre-existing hypotension (systolic blood pressure less than 110 mm Hg), or orthostatic hypotension~* Insulin-dependent diabetes~* Chronic kidney or liver failure~* Pancreatitis or gout~* Meniere's disease, benign positional vertigo, or narcolepsy~* Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist~* Currently taking another alpha-1 antagonist agent~* Pregnant~* DSM-IV diagnosis of cognitive disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or other psychotic disorder~* Current delirium~* Active substance dependence disorder within 3 months of study entry~* Current substance use other than alcohol (no more than 2 drinks per day)~* Severe psychiatric instability or situational life crises, including evidence of suicidal or homicidal ideation~* Currently taking any other psychotropic medication (e.g., antidepressants, benzodiazepines, anti-convulsants, anti-psychotics, sedating antihistamines, sedatives/hypnotics (exclusionary medications will be discontinued and participants will undergo a 2-week washout period before baseline assessments)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive treatment with prazosin plus psychotherapy
- 2 (Type: PLACEBO_COMPARATOR): Participants will receive treatment with placebo plus psychotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients before elective Heart valve - or aortocoronary by pass surgery with heart-lung-machine.~Exclusion Criteria:~* Pregnant patients~* Patients with preoperative atrial fibrillation and/or hyperthyreosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Placebo globules group (Type: PLACEBO_COMPARATOR): Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
- Nux vomica group (Type: ACTIVE_COMPARATOR): Patients receive Nux vomica globules made out of sugar sublingually before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ischemic Preconditioning After Aortic Clamping

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with an aortic aneurysm requiring open surgery (with no possibility of endovascular surgery)~* Patients who received clear information, with signed consent~* Patients 18 to 85 years~Exclusion criteria:~* Patients under guardianship~* No possibility to give the patients clear information (comprehension difficulties, emergency surgery)~* Pregnancy, lactation~* Hemodialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ischemic preconditioning arm (Type: EXPERIMENTAL): Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
- Control patients (Type: OTHER): Usual surgery assigned to control patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients ages 0 to 6 months who do need meet the criteria at the initial appointment for supraglottoplasty~* Seen in University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh (CHP) Otolaryngology Department~* Laryngomalacia without prolonged (\>20 seconds) cyanosis, apnea, nor failure to thrive.~Exclusion Criteria:~* Children over the age of 6 months old will be excluded from participation.~* Premature infants (\<37 weeks gestation)~* Patients with lung disease.~* Laryngomalacia with prolonged (\>20 seconds) cyanosis, apnea, and failure to thrive~* Sleep induced laryngomalacia~* Patients with craniofacial abnormalities~* Patients with a syndrome~* Patients with additional airway abnormalities, seen before or at consult~* Patients with symptoms that necessitate surgery~* Patients with a prior cardiac surgery~* Patients with AST prescribed prior to the initial otolaryngology consult.

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Speech Language Therapy Alone (Type: EXPERIMENTAL): Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
- Speech Language Therapy and Acid Suppression Therapy (Type: ACTIVE_COMPARATOR): Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues